Physician profile
Daniel Farray-Berges
NPI 1639116288
$3,076.49
in general payments reported to CMS, 2019-2025
34 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.79 · 2020: $962 · 2021: $215 · 2022: $266 · 2023: $371 · 2024: $414 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.88 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,258.31 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $316.10 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.77 | 2019-2024 | |
| Boston Scientific Corporation | $150.05 | 2022-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Janssen Pharmaceuticals, INC | $127.90 | 2020-2021 | |
| Janssen Biotech, INC. | $104.15 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Astellas Pharma Global Development | $88.10 | 2021 | |
| Eisai INC. | $87.83 | 2023-2025 | |
| Glaxosmithkline, LLC. | $85.59 | 2024-2025 | Ojjaara, Blenrep |
| Gilead Sciences, INC. | $81.30 | 2021-2024 | |
| Celgene Corporation | $71.79 | 2023-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Seagen INC. | $57.81 | 2020-2022 | |
| Genentech USA, INC. | $44.09 | 2025 | Tecentriq Hybreza |
| Exelixis INC. | $39.66 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $32.44 | 2023 | |
| Tempus Ai, INC | $23.81 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.65 | 2025 | Libtayo |
| Medtronic, INC. | $23.46 | 2024 | Osteocool Rf Ablation System |
| Amgen INC. | $23.04 | 2025 | Vectibix |
| Array Biopharma INC | $21.26 | 2025 | Braftovi, Mektovi, Lorbrena |
| Merck Sharp & Dohme LLC | $20.13 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2024 | |
| Geron Corporation | $19.94 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $19.31 | 2022 | |
| Puma Biotechnology, INC. | $19.22 | 2024 | |
| Morphosys, US INC. | $16.86 | 2022 | |
| Genzyme Corporation | $16.40 | 2023 | |
| Kite Pharma, INC. | $15.50 | 2022 | |
| Astellas Pharma US INC | $14.11 | 2025 | Vyloy |
| Sirtex Medical INC | $10.38 | 2023 | Sir-Spheres Microspheres |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Farray-Berges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.